GERMANY

EQS-News: Cryptology Asset Group p.l.c. (“Cryptology”) & Deutsche Digital Assets (“DDA”) - Joint Press Release

Retrieved on: 
Thursday, February 2, 2023

Deutsche Digital Assets (“DDA”) & Cryptology Asset Group p.l.c.

Key Points: 
  • Deutsche Digital Assets (“DDA”) & Cryptology Asset Group p.l.c.
  • FRANKFURT, GERMANY & SLIEMA, MALTA, January 17, 2023 – Patrick Lowry, Co-founder and CEO of crypto asset management group Deutsche Digital Assets (“DDA”) as well as publicly-listed crypto holding company Cryptology Asset Group p.l.c.
  • (“Cryptology”), resigned his role as CEO and Managing Partner of DDA and its subsidiaries, which became effective January 1, 2023.
  • Moving forward, Patrick will focus his efforts on Cryptology, which has also acquired DDA’s US-based operations, while remaining an active shareholder in DDA.

EQS-News: Evotec completes acquisition of Central Glass Germany

Retrieved on: 
Monday, November 7, 2022

AS EVOTEC DRUG SUBSTANCE (GERMANY) GMBH, THE ACQUISITION STRENGTHENS EVOTECS CLINICAL AND COMMERCIAL DRUG SUBSTANCE MANUFACTURING CAPACITY AND CAPABILITY ESPECIALLY FOR RARE DISEASES AND PRECISION THERAPEUTICS

Key Points: 
  • AS EVOTEC DRUG SUBSTANCE (GERMANY) GMBH, THE ACQUISITION STRENGTHENS EVOTECS CLINICAL AND COMMERCIAL DRUG SUBSTANCE MANUFACTURING CAPACITY AND CAPABILITY ESPECIALLY FOR RARE DISEASES AND PRECISION THERAPEUTICS
    Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the acquisition of Central Glass Germany GmbH from the Japanese chemical manufacturing company Central Glass Co. Ltd., signed in August 2022, has been completed.
  • As Evotec Drug Substance (Germany) GmbH (Evotec DS), the strategic transaction strengthens Evotecs clinical and commercial manufacturing capacity and capability for small molecule therapeutics.
  • Located in Halle/Westphalia, Germany, Evotec DS comprises a team of approximately 60 highly skilled chemical manufacturing experts and a fully operational EU cGMP certified facility.
  • Evotec DS provides a high-quality, European-based solution to Evotecs partners for the development and commercialisation of drug substances, especially for rare diseases and precision therapeutics.

EQS-News: FUCHS PETROLUB SE: Industrial-scale pilot plant for production of high-performance battery electrolytes

Retrieved on: 
Thursday, September 22, 2022

The first pilot production line for high-performance battery electrolytes is set to commence operations at the FUCHS location in Kaiserslautern in October 2022.

Key Points: 
  • The first pilot production line for high-performance battery electrolytes is set to commence operations at the FUCHS location in Kaiserslautern in October 2022.
  • The globally operating FUCHS Group first announced its investment in E-Lyte Innovations GmbH back in May.
  • After just a short construction period, the state-of-the-art and flexible pilot plant will soon be ready to begin production.
  • Additionally to the pilot plant, a state-of-the-art production facility will also be constructed in Kaiserslautern.

DGAP-News: XPhyto Therapeutics Corp.: XPhyto Pursues Potential Application of its Oral Dissolvable Biosensor Inflammation Test for Buprenorphine-related Dental Disease

Retrieved on: 
Monday, July 18, 2022

VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / July 18, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY),(OTCQB:XPHYF), (FSE:4XT) ("XPhyto" or the "Company") is pleased to report a significant potential market opportunity for its oral dissolvable ("ODF") biosensor screening tests for oral inflammation.

Key Points: 
  • VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / July 18, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY),(OTCQB:XPHYF), (FSE:4XT) ("XPhyto" or the "Company") is pleased to report a significant potential market opportunity for its oral dissolvable ("ODF") biosensor screening tests for oral inflammation.
  • XPhyto is investigating the potential application of one or more of its ODF biosensor screening tests for oral inflammation to detect buprenorphine-related dental problems.
  • The Company's oral dissolvable inflammation screening test was EU registered in late 2021 and is currently licensed for marketing and sale in Europe.
  • The Company is currently investigating the potential application of one or more of its oral health biosensor screening tests for the detection of buprenorphine-related dental problems.

Dialysis Equipment Market Research Report 2022: Synthetic High-flux Membranes and Unmodified Cellulose Low-flux Membranes - Global Forecast to 2027 - Increasing Demand For Peritoneal Dialysis Devices - ResearchAndMarkets.com

Retrieved on: 
Monday, May 23, 2022

GLOBAL DIALYSIS EQUIPMENT MARKET SIZE, BY UNMODIFIED CELLULOSE LOW-FLUX MEMBRANES, 2019-2027 (USD BILLION)

Key Points: 
  • GLOBAL DIALYSIS EQUIPMENT MARKET SIZE, BY UNMODIFIED CELLULOSE LOW-FLUX MEMBRANES, 2019-2027 (USD BILLION)
    FIGURE 8.
  • GLOBAL DIALYSIS EQUIPMENT MARKET SIZE, BY UNMODIFIED CELLULOSE LOW-FLUX MEMBRANES, BY REGION, 2021 VS 2027 (USD BILLION)
    FIGURE 9.
  • GLOBAL DIALYSIS EQUIPMENT MARKET SIZE, BY DIALYSIS CENTERS, 2019-2027 (USD BILLION)
    FIGURE 26.
  • GLOBAL DIALYSIS EQUIPMENT MARKET SIZE, BY UNMODIFIED CELLULOSE LOW-FLUX MEMBRANES, BY REGION, 2019-2027 (USD BILLION)
    TABLE 10.

Focus on sustainability: Sedus sets an example furnishing CAMPUS GERMANY at Expo 2020 Dubai

Retrieved on: 
Friday, February 18, 2022

DOGERN, Germany, Feb. 18, 2022 /PRNewswire/ -- The German Pavilion at Expo 2020 Dubai focuses on the subtheme of sustainability. At the Expo, the motto says it all: The exhibition is pursuing the ambitious goal of becoming one of the most sustainable Expos ever. In addition to the generation and use of clean energy, water consumption is reduced by using intelligent systems.

Key Points: 
  • DOGERN, Germany, Feb. 18, 2022 /PRNewswire/ -- The German Pavilion at Expo 2020 Dubai focuses on the subtheme of sustainability.
  • "It is not only because of comfort and ergonomics that Sedus products create a sense of well-being.
  • All products that you find in Dubai have been produced in Germany in compliance with the highest quality standards.
  • "At Expo Dubai, we can demonstrate the diversity of our solutions for the modern office and we are very proud of that," says Holzapfel.

Focus on sustainability: Sedus sets an example furnishing CAMPUS GERMANY at Expo 2020 Dubai

Retrieved on: 
Friday, February 18, 2022

DOGERN, Germany, Feb. 18, 2022 /PRNewswire/ -- The German Pavilion at Expo 2020 Dubai focuses on the subtheme of sustainability. At the Expo, the motto says it all: The exhibition is pursuing the ambitious goal of becoming one of the most sustainable Expos ever. In addition to the generation and use of clean energy, water consumption is reduced by using intelligent systems.

Key Points: 
  • DOGERN, Germany, Feb. 18, 2022 /PRNewswire/ -- The German Pavilion at Expo 2020 Dubai focuses on the subtheme of sustainability.
  • "It is not only because of comfort and ergonomics that Sedus products create a sense of well-being.
  • All products that you find in Dubai have been produced in Germany in compliance with the highest quality standards.
  • "At Expo Dubai, we can demonstrate the diversity of our solutions for the modern office and we are very proud of that," says Holzapfel.

DGAP-News: XPhyto Therapeutics Corp.: XPhyto Epilepsy Clinical Trial Planned in 2022 with Its Proprietary Fast-Dissolving CBD Oral Strips

Retrieved on: 
Monday, December 20, 2021

VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / December 15, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to provide an update on the development of its fast-dissolving CBD oral strips.

Key Points: 
  • VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / December 15, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to provide an update on the development of its fast-dissolving CBD oral strips.
  • Prof. Dr. Beckert said, "the clinical trial of our CBD product is aiming to demonstrate the efficient and precise dosing of the treatment.
  • If successful, this could make a significant difference to Epilepsy patients and we are excited to commence the trial next year."
  • XPhyto is developing a hybrid-generic CBD prescription drug formulation that employs the Company's proprietary oral dissolvable ("ODF") platform to deliver precise and efficient CBD dosages for the treatment of certain forms of childhood Epilepsy.

DGAP-News: XPhyto Therapeutics Corp.: XPhyto Completes Strategic Acquisition of 3a-diagnostics GmbH

Retrieved on: 
Monday, December 6, 2021

"The strategic acquisition of 3a is a transformative step in XPhyto's commercial strategy," said Peter Damouni, XPhyto director.

Key Points: 
  • "The strategic acquisition of 3a is a transformative step in XPhyto's commercial strategy," said Peter Damouni, XPhyto director.
  • "The integration of a highly innovative European biosensor development company places XPhyto at the forefront of the rapid point-of-care test industry, an explosive and technology driven sector.
  • This transaction is the second acquisition since going public in August 2019.
  • XPhyto completed the takeover of Vektor Pharma TF GmbH in September 2019.